Monitoring of Early Warning Indicators for HIV Drug Resistance in Antiretroviral Therapy Clinics in Zimbabwe by Dzangare, J. et al.
S U P P L E M E N T A R T I C L E
Monitoring of Early Warning Indicators for HIV
Drug Resistance in Antiretroviral Therapy Clinics
in Zimbabwe
J. Dzangare,1 E. Gonese,3 O. Mugurungi,1 T. Shamu,1 T. Apollo,1 D. E. Bennett,3 K. F. Kelley,4 M. R. Jordan,4,5
C. Chakanyuka,2 F. Cham,6 and R. M. Banda2
1Ministry of Health and Child Welfare, and 2World Health Organization, Harare, Zimbabwe; 3Centers for Disease Control and Prevention, Atlanta,
Georgia; 4World Health Organization, Geneva, Switzerland; 5Tufts University School of Medicine, Boston, Massachusetts; and 6QUALABS Consulting
Inc, Hartford, Connecticut
Monitoring human immunodeficiency virus drug resistance (HIVDR) early warning indicators (EWIs) can
help national antiretroviral treatment (ART) programs to identify clinic factors associated with HIVDR
emergence and provide evidence to support national program and clinic-level adjustments, if necessary. World
Health Organization–recommended HIVDR EWIs were monitored in Zimbabwe using routinely available
data at selected ART clinics between 2007 and 2009. As Zimbabwe’s national ART coverage increases,
improved ART information systems are required to strengthen routine national ART monitoring and
evaluation and facilitate scale-up of HIVDR EWI monitoring. Attention should be paid to minimizing loss to
follow-up, supporting adherence, and ensuring clinic-level drug supply continuity.
Zimbabwe has an estimated national human immuno-
deficiency virus (HIV) prevalence of 14.3%. Anti-
retroviral treatment (ART) scale-up started in 2004, and
by the end of 2009 more than 220 000 (37%) of the
600 000 estimated people in need were receiving
therapy [1]. At present, HIV care and ART services are
being decentralized to primary care clinics in order to
improve access to HIV care. As ART is scaled up and
access expands, appropriate program monitoring
should be instituted to optimize quality of care and
minimize situations that favor the emergence of HIV
drug resistance (HIVDR). Zimbabwe’s National HIV
Drug Resistance Working Group, led by the Ministry of
Health and Child Welfare, developed a population-
based HIVDR prevention and assessment strategy
that includes monitoring of World Health
Organization (WHO)–recommended HIVDR early
warning indicators (EWIs) [2]. Early warning in-
dicators monitor factors associated with HIVDR using
information routinely recorded in medical and phar-
macy records, and results provide ART programs with
an evidence base to take corrective action at clinic and
national program levels to minimize the emergence of
population-level HIVDR.
Based on data routinely collected in its existing
medical and pharmacy records, Zimbabwe monitored
the following EWIs: ART prescribing practices; pro-
portion of patients lost to follow-up 12 months after
ART initiation; proportion of patients still on ap-
propriate first-line ART 12 months after initiation;
on-time antiretroviral (ARV) drug pickup; on-time
clinic appointment keeping; and ARV drug supply
continuity.
Appropriate first-line ART regimens were defined as
regimens listed in national ART guidelines or a regimen
recommended by WHO 2006 treatment guidelines.
Patients were classified as lost to follow-up if they did
not pick up their ARVs or attend a clinic appoint-
ment within 90 days after the last scheduled ARV
pickup or last scheduled clinic appointment. On-time
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drug pickups were defined as pickups that occurred before the
previous ARVs would have run out if taken as prescribed. On-
time appointment keeping was defined as attending an ap-
pointment #7 days after the appointment was scheduled to
take place.
For each year under review, a number of ART clinics were
selected for assessment based on geographic distribution, levels
of service delivery, population served, and feasibility.
SAMPLING METHOD AND DATA ANALYSIS
For patients initiating ART in 2007 and 2008, a sample of
eligible patients was chosen from a period of either 3 months
or 6 months, depending on the clinic’s ART patient case load,
in order to achieve a sample size of at least 100 individuals,
following 2007 WHO EWI guidance [3].
For patients initiating ART in 2009, a minimum sample size
for each clinic was determined based on the total number of
patients initiating ART at the selected clinics permitting esti-
mation of a 95% confidence interval plus or minus 7% [4].
Retrospective data were abstracted from records of patients
consecutively initiating ART or consecutively picking up
ARVs on or after 1 January of each year under review until the
designated sample size was reached [4].
In all years, data for each indicator were directly recorded
and analyzed using a standardized electronic EWI tool de-
veloped by WHO [5]. Abstracted data included ART initiation
date, ART regimen prescribed, dates of scheduled and kept clinic
appointments, dates of drug pickups, number of days of ARVs
dispensed, and dates of deaths and transfers out, if applicable.
Pharmacy stock cards were used to determine stockouts for each
ARV routinely used at the clinic from 1 January to 31 December
of each year. Reliability of data was checked by a review of
10% of records at all clinics and in some cases by use of other
sources for the same data (eg, a pharmacy record was used to
check reliability of a prescription date abstracted from the
ART card).
Early warning indicators were piloted at 17 ART clinics in
2007 and monitored at 40 clinics in 2008. In 2009, because
a revised WHOmethod [4] and electronic abstract tool [5] were
used, only 24 clinics were monitored. Only 8 clinics participated
in all 3 years of monitoring; thus, trends were assessed only in
these 8 clinics.
RESULTS
Overall prescribing practices followed national guidelines in
all sites across all years (Table 1). Although trends cannot be
reliably calculated because different clinics were included in
different years, the proportion of ART clinics meeting the
WHO-recommended target for appropriate prescribing
practices appeared to increase from 65% (11 of 17) in 2007 to
96% (23 of 24) in 2009. Over the same time period, the pro-
portion of facilities meeting the minimum target of #20%
for loss to follow-up declined from 70% to 33.3%, whereas the
proportion of patients retained on appropriate first-line ART
at 12 months did not differ significantly over the same period.
Of the 8 clinics where EWI data were collected consecutively
in 2007, 2008, and 2009, prescribing practices improved over
time (Figure1A and 1B). Only 1 clinic did not meet the
Table 1. Percentage of Antiretroviral Treatment Clinics Monitored in 2007, 2008, and 2009 Achieving the World Health Organization Early
Warning Indicator Targets
ART Clinics Achieving the EWI Target, %
Indicator EWI Target for All Clinics, % 2007 (n 5 17) 2008 (n 5 40) 2009 (n 5 24)
Adult patients initiating ART who were initially
prescribed an appropriate first-line ART
regimena
100 65 92.5 96
Patients initiating ART at a site who were lost
to follow-up 12 mo after initiation
#20 70 52.5 33.3
Patients who were taking an appropriate
first-line ART regimen 12 mo after ART
initiation
$80 53 35 45.8
Patients on ART who picked up ARV drugs on
time
$70 ND ND 80 (n 5 10)
ART patients who attended clinical
consultations on time
$90 ND ND 80 (n 5 10)
Months during a designated year with no ARV
drug stockouts
100 ND 57 22 (n 5 18)
Abbreviations: ART, antiretroviral treatment; ARV, antiretroviral; EWI, early warning indicator; ND, EWI not assessed.
a Appropriate regimens were defined as regimens following national or World Health Organization first-line ART prescribing guidelines.
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prescribing practices target in 2007 and 2009, and the pro-
portion of ART clinics achieving the minimum target for patient
retention on first-line ARVs did not vary over time (Figure 1C).
Rates of loss to follow-up generally increased over time at all 8
sites (Figure 1D).
For cohorts initiating ART in 2007 and 2008, dates of ARV
drug pickup were often found to be inconsistent when com-
paring individual patient ART cards and pharmacy registers,
which made assessment of on-time ARV pickup particularly
problematic. Additionally, ARV supply continuity could not be
assessed at some clinics prior to 2009 due to incomplete phar-
macy records.
DISCUSSION
The public health approach to ART scale-up in resource-limited
settings involves the use of standardized and simplified treat-
ment regimens consistent with international standards and ap-
propriate to local circumstances [2]. Use of the public health
approach for HIV treatment has led to substantial decline in
AIDS-related morbidity and mortality in sub-Saharan Africa.
However, HIVDR emergence remains a major concern for
national ART programs; hence, strategies to prevent first-
line ART failure are essential for the long-term success of
ART in sub-Saharan Africa. The widespread use of fixed-dose
combination ART in Zimbabwe has reduced pill burden and
improved ART adherence.
At present, individual HIVDR testing is neither available nor
recommended in Zimbabwe. However, the lack of individual
HIVDR testing need not limit the optimization of HIV care and
treatment. Care may be optimized and HIVDR minimized
through the strengthening of healthcare systems and routine
assessment of programmatic factors associated with HIVDR
emergence [3, 6].
In Zimbabwe, prescribing practices generally follow the na-
tional guidelines. In some cases, low rates of patient retention on
first-line therapy at 12 months and high rates of loss to follow-
up may have been driven by poor record keeping or missing
information. Nonetheless, detailed clinic-level investigations to
determine reasons for high rates of loss to follow-up and low
rates of retention on first-line ART at 12 months are urgently
needed. An important indicator of population-level adher-
ence to ART is the assessment of on-time ARV pickup, which
has been shown to be associated with viral load suppression
[6, 7]. However, prior to 2009, monitoring of on-time ARV
pickups was not feasible because pharmacy records did not
Figure 1. Percentage of antiretroviral treatment clinics achieving the World Health Organization early warning indicator targets: 8 clinics monitored
in 2007, 2008 and 2009. A, Overall early warning indicators. B, Prescribing practices. C, Loss to follow-up. D, Patient retention. WHO, World Health
Organization.
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permit data abstraction and inconsistencies were observed be-
tween individual patient records and pharmacy dispensing logs.
Health system factors associated with failure to achieve EWI
targets included inadequate clinic staff, poor record keeping, and
long travel distances for patients. Additionally, labor-related
population mobility was cited by some clinics, especially those
close to international borders and in major cities, as a barrier to
patient on-time drug pickup and patient tracing.
Evidence from other countries suggests that reducing finan-
cial burden to patients may improve access to and increase
patient retention in care [8, 9]. High transport costs due to
hyperinflation may have contributed to high patient loss to
follow-up rates and subsequent low patient retention rates at
clinics. Patients receiving ART from clinics with large catch-
ment areas may have longer distances to travel and may have
reduced access to services. Because of the economic situation,
even patients with good ART adherence may encounter bar-
riers to taking their ARVs consistently. Individuals who fail to
access care or who discontinue ART have the greatest risk of
disease progression and death [9] and constitute Zimbabwe’s
highest HIV/AIDS-related public health priority. Providing
ARVs for longer periods and decentralized service delivery may
help to reduce frequency of patient visits and transportation
costs.
Among the clinics monitored, loss to follow-up was recog-
nized as a significant problem, and innovative ways of tracing
patients through use of volunteers and community-based
organizations should be considered on a large scale to mini-
mize loss to follow-up. Additionally, supporting on-time clinic
attendance and ARV pickups through mobile phone technol-
ogies and community-based treatment supporters and health
workers should be explored. Importantly, the fact that many
EWIs were difficult to monitor due to poor record keeping and
missing information underscores the urgency of medical and
pharmacy record strengthening and standardization. Addi-
tional resources are needed to optimize ART clinic record
keeping and to increase local and national supervision to en-
sure successful scale-up of program-based monitoring and
evaluation in the future.
CONCLUSIONS
As ART is scaled up, monitoring of situations known to favor
emergence of HIVDR is critical to the success of Zimbabwe’s
national ART program. Early warning indicator monitoring
has informed the national program about strengths and
limitations in existing medical and pharmacy record systems
and has identified clinic-specific barriers to HIVDR pre-
vention. Urgent public health actions include support for
improved clinic record keeping and innovative solutions to
minimize loss to follow-up and maximize on-time clinic ap-
pointment keeping and ARV pickups.
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